Zachary Hafner
At last count, the pharmaceutical industry’s new product pipeline included more than 7,000 products in late-stage development, roughly half of which are deemed “specialty.” The reality is, our health care system is poorly equipped to address this issue head-on.
Roughly one in 20 women of childbearing age suffer from major depression. Women without private health insurance had a 2.5-fold increased risk of major depression. The antidepressants most commonly used by women with major depression were selective serotonin reuptake inhibitors (21.3%), phenylpiperazines (8.4%), and serotonin-norepinephrine reuptake inhibitors (7.2%).
There are four barriers to improving colorectal care for poor people. They are: limited resources, whether patients understand colorectal symptoms and physicians correctly diagnose them, beliefs about health and illness such as self-care, and patients’ reaction to illness.
News Wire
Incidence increased 61% over a 14-year period
Agent can also be used perioperatively in some patients to reduce the need for transfusions
Lucemyra indicated for up to 14 days as part of a long-term treatment plan
Novel drug is a first-in-class treatment that reduces migraine occurrence
Drug indicated for use prior to surgery to boost platelet counts
Sarah Kwon
Cancer treatment is advancing rapidly but at eye-popping prices. Six-figure oncology drugs are increasingly common, necessitating new approaches that will bring the drugs back into the orbit of affordability. The notion that drug payment based on value rather than volume could help reduce drug costs…
François de Brantes
It’s no mystery why this country has both the highest per capita health care costs and the lowest overall percentage of people with coverage. The two are connected, but as if on a teeter-tooter: As one goes up, the other goes down.
Saurabh Nagar, BPharm
Resource use and exacerbation among patients with COPD are weighed in a preliminary study. Subjects treated with a combination of long-acting muscarinic antagonists (LAMA) and long-acting β2-adrenergic agonists (LABA) cost more to manage than those receiving LAMA alone, although emergency department and outpatient visit costs were less. The authors say those starting the LAMA+LABA therapy may have more severe COPD.

Miracles Aren’t Cheap: How Can the Health Care System Pay for New Cancer Treatments?

Lee Newcomer, MD, a former senior vice president at UnitedHealthcare puts it succinctly in our cover story: “We have a limited set of dollars.”

Take CAR-T therapies, for example. Our story shows just how financially perplexing this can get. The $475,000 one-time cost of Kymriah exceeds the cost for conventional chemotherapy by almost $330,000. It would also provide a child with about eight extra years of life on average. Who’s going to say “no?”

One way of dealing with price concerns is through indication-specific drug pricing. The idea is gaining steam, and an IMS report states that by 2020 most new oncology drugs will have three or more indications.

Does anyone have any solution about balancing cost, outcomes, and human decency?

June 11-12, 2018
June 11-12, 2018
June 11-12, 2018
June 17-18, 2018
A British study of 296,535 people added to evidence that the so-called obesity paradox—that being overweight or obese does not necessarily mean a greater chance of getting a heart attack—simply does not exist. Many of us could stand to lose a few pounds to lower our cardiovascular risk.
Peter Boland
On the one hand, the PCMH is an admirable effort to gather in one place all the disparate and disorganized clinical and social supports the patient needs. At the same time, though, medical homes employ provider-defined business models and conventional performance measures, belying the patient-centered in the name.
Charlotte Huff
The deadliness of liver cancer is undisputed, but a growing body of data shows that too often, patients, and particularly those who are uninsured or nonwhite, miss out on earlier diagnosis and potentially life-saving surgery.